Viridian Therapeutics, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
VRDN Company Description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
VRDN Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view VRDN Smart Score
Score Breakdown
VRDN Company Description
Show More
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of VRDN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by VRDN's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of VRDN in WallStreetBets Daily Discussion
VRDN News
Recent insights relating to VRDN
CNBC Recommendations
Recent picks made for VRDN stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in VRDN
Corporate Flights
Flights by private jets registered to VRDN
Our Analysis